Sonnet BioTherapeutics (SONN) Competitors $2.81 -0.51 (-15.36%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.79 -0.02 (-0.68%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SONN vs. SNTI, GANX, PRLD, AADI, ATHE, EGRX, JSPR, CVM, RNXT, and PEPGShould you be buying Sonnet BioTherapeutics stock or one of its competitors? The main competitors of Sonnet BioTherapeutics include Senti Biosciences (SNTI), Gain Therapeutics (GANX), Prelude Therapeutics (PRLD), Aadi Bioscience (AADI), Alterity Therapeutics (ATHE), Eagle Pharmaceuticals (EGRX), Jasper Therapeutics (JSPR), CEL-SCI (CVM), RenovoRx (RNXT), and PepGen (PEPG). These companies are all part of the "pharmaceutical products" industry. Sonnet BioTherapeutics vs. Its Competitors Senti Biosciences Gain Therapeutics Prelude Therapeutics Aadi Bioscience Alterity Therapeutics Eagle Pharmaceuticals Jasper Therapeutics CEL-SCI RenovoRx PepGen Sonnet BioTherapeutics (NASDAQ:SONN) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk. Do analysts recommend SONN or SNTI? Sonnet BioTherapeutics presently has a consensus target price of $20.00, suggesting a potential upside of 611.74%. Senti Biosciences has a consensus target price of $8.50, suggesting a potential upside of 405.95%. Given Sonnet BioTherapeutics' higher probable upside, research analysts clearly believe Sonnet BioTherapeutics is more favorable than Senti Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonnet BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Senti Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of SONN or SNTI? 9.5% of Sonnet BioTherapeutics shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 2.0% of Sonnet BioTherapeutics shares are held by insiders. Comparatively, 3.1% of Senti Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media refer more to SONN or SNTI? In the previous week, Sonnet BioTherapeutics had 2 more articles in the media than Senti Biosciences. MarketBeat recorded 2 mentions for Sonnet BioTherapeutics and 0 mentions for Senti Biosciences. Senti Biosciences' average media sentiment score of 0.00 beat Sonnet BioTherapeutics' score of -0.50 indicating that Senti Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Sonnet BioTherapeutics Negative Senti Biosciences Neutral Is SONN or SNTI more profitable? Senti Biosciences' return on equity of -177.24% beat Sonnet BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sonnet BioTherapeuticsN/A -777.92% -271.32% Senti Biosciences N/A -177.24%-67.38% Which has more risk & volatility, SONN or SNTI? Sonnet BioTherapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500. Which has higher valuation and earnings, SONN or SNTI? Sonnet BioTherapeutics has higher revenue and earnings than Senti Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSonnet BioTherapeutics$20K445.39-$7.44MN/AN/ASenti BiosciencesN/AN/A-$52.79M-$10.84-0.15 SummarySenti Biosciences beats Sonnet BioTherapeutics on 7 of the 11 factors compared between the two stocks. Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SONN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SONN vs. The Competition Export to ExcelMetricSonnet BioTherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.51M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.08%P/E RatioN/A17.6228.6723.80Price / Sales445.39179.18373.9066.65Price / CashN/A41.9535.4557.96Price / Book-3.968.508.275.55Net Income-$7.44M-$55.06M$3.24B$259.03M7 Day Performance-29.57%-3.98%-3.69%-4.59%1 Month Performance-32.29%9.59%4.33%4.46%1 Year Performance-56.36%6.72%25.95%18.03% Sonnet BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SONNSonnet BioTherapeutics2.1568 of 5 stars$2.81-15.4%$20.00+611.7%-55.5%$10.51M$20K0.0010Short Interest ↑Gap DownSNTISenti Biosciences1.7473 of 5 stars$1.89+0.9%$8.50+350.7%-22.2%$49.19M$2.56M-0.174GANXGain Therapeutics2.303 of 5 stars$1.63+0.9%$8.20+401.8%+35.8%$49.13MN/A-1.9020Upcoming EarningsPRLDPrelude Therapeutics3.1414 of 5 stars$0.86-7.5%$4.50+423.3%-85.3%$48.56M$7M-0.51120High Trading VolumeAADIAadi Bioscience0.4862 of 5 stars$1.95+0.5%$1.67-14.5%+15.1%$48.16M$25.07M-0.8640Upcoming EarningsATHEAlterity Therapeutics1.7589 of 5 stars$5.42-3.0%$12.00+121.6%+234.0%$48.02MN/A0.0010Upcoming EarningsGap DownEGRXEagle Pharmaceuticals1.9805 of 5 stars$3.69flatN/A-33.3%$47.92M$257.55M0.00100Gap DownJSPRJasper Therapeutics2.7047 of 5 stars$3.17+2.1%$29.75+840.0%-83.4%$47.54MN/A-0.6020CVMCEL-SCI1.2111 of 5 stars$8.89+3.2%N/A-72.6%$47.28MN/A-18.5143Positive NewsShort Interest ↑RNXTRenovoRx2.3268 of 5 stars$1.28+2.0%$7.25+468.6%-1.6%$46.63M$40K-3.196Analyst DowngradePEPGPepGen2.6609 of 5 stars$1.43-1.7%$7.67+438.0%-86.9%$46.63MN/A-0.4630Gap Down Related Companies and Tools Related Companies Senti Biosciences Competitors Gain Therapeutics Competitors Prelude Therapeutics Competitors Aadi Bioscience Competitors Alterity Therapeutics Competitors Eagle Pharmaceuticals Competitors Jasper Therapeutics Competitors CEL-SCI Competitors RenovoRx Competitors PepGen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SONN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
